

EICADD Center Ajman

Director's Report on Developmental Progress Assessment

Date of Visit: 14-10-2025

Child's Name: Ayala Abu Sweis

Date of Birth: 10-10-2020

Age: 4 years 11 months

Gender: Male

Guardian: NA

Overview:

Ayala visited our center for a developmental progress assessment. The current evaluation indicates that the child presents with **information processing delays** and **regressive cognitive and developmental delays**, which collectively contribute to the observed symptoms and make the child appear symptomatically more affected.

Genetic findings confirm the presence of an **SGSH gene mutation**, consistent with **Mucopolysaccharidosis Type III-A (Sanfilippo Type A)**. This mutation directly affects **lysosomal function and neuronal development**, leading to **white matter delay** and disruption in **brain signaling and processing efficiency**.

These findings explain the observed developmental regression and fluctuations in cognitive and behavioral performance. The focus moving forward will be on supporting neuroplasticity, mitigating the neuroinflammatory effects of the condition, and stabilizing cognitive and adaptive functions through structured intervention.

Further analyses and consistent therapeutic engagement are recommended to ensure ongoing monitoring and individualized optimization of progress.

Recommended Plan:

1. Development Protocol for Information Processing

- Continue the **developmental protocol** focusing on enhancing information processing and adaptive learning.
- Maintain the program for **4 months**, followed by a **reevaluation**, preferably conducted in person.
- Establish a **new baseline** to monitor progress and track neurodevelopmental response to intervention.
- Continue structured home reinforcement and parent-guided engagement.

2. Main Recommended Analyses (Next Evaluation):

The recommended analyses are performed through **Neurazon (Canada)**, a bioinformatics company partnered with accredited international laboratories.

These are **external recommendations**, not obligatory, and **not conducted directly through our centers**.

They aim to provide deeper biological and functional insight into the child's developmental profile and guide individualized intervention planning.

3. Recommended Therapy:

- **Neuroplasticity Rehabilitation Therapy (Intensive – Continue):**

Continue with intensive neuroplasticity-based rehabilitation therapy on a regular basis to support neuronal connectivity, processing speed, and adaptive developmental function.

The therapy should focus on structured cognitive, speech, and motor integration exercises to slow regression and enhance neurodevelopmental resilience.

Notes on External Testing:

The recommended analyses are performed through **Neurazon (Canada)**, a bioinformatics company partnered with accredited international laboratories.

These are **external recommendations**, not obligatory, and **not conducted directly through our centers**.

They aim to provide deeper biological and functional insight into the child's developmental profile and guide individualized intervention planning.

Disclaimer:

This assessment is **not a final diagnosis**, but a developmental evaluation based on the current findings.

The child is open to improvement through continued neuroplasticity rehabilitation and structured support.

This report remains **valid for 4 months** from the date of assessment.

The recommended analyses are **external and optional**, provided through **Neurazon (Canada)** to complement the clinical and developmental evaluation.



Signature:

EICADD Center Ajman Director.

This report is valid for 4 months from the date of assessment.

Signature:

EICADD Center

Center's Leading Staff:


Speech Therapist: Ms. Amira Alomari

Occupational Therapist: Ms. Malak Jaber

Psychologist and behaviour therapist: Ms. Asmaa Alshanawi

EICADD Center Director

Dr. Noraddin Al-Dan



EICADD